Nonagen Bioscience (United States)

Recent papers from Nonagen Bioscience (United States)

1. Prospective multicenter validation of a Urine-Based multiplex assay for risk stratification of patients presenting with gross hematuria.2026
2. Detection of bladder cancer in patients with microscopic hematuria using Oncuria-Detect: results of a prospective, multicenter international studyJournal of Translational Medicine · 2026
3. Developing a prediction model in a large case-control study for the early detection of bladder cancerJournal of Translational Medicine · 2025
4. Diagnostic Accuracy of the Oncuria-Detect Multiplex Immunoassay in Detecting Upper Tract Urothelial CarcinomaThe Journal of Urology · 2025
5. Development and analytical validation of a multiplex diagnostic qPCR-array as a potential application in predicting the response to neoadjuvant chemotherapy in muscle invasive bladder cancerTranslational Oncology · 2025
6. Expanded Performance Comparison of the Oncuria 10-Plex Bladder Cancer Urine Assay Using Three Different Luminex xMAP InstrumentsDiagnostics · 2025
7. Performance of the Oncuria-Detect bladder cancer test for evaluating patients presenting with haematuria: results from a real-world clinical settingJournal of Translational Medicine · 2025
8. Effects of Different Voided Urine Sample Storage Time, Temperature, and Preservatives on Analysis with Multiplex Bead-Based Oncuria Bladder Cancer ImmunoassayDiagnostics · 2025
9. Distribution and Functional Significance of KLF15 in Mouse Cerebellum2024
10. Abstract A006: Bladder cancer risk stratification with the Oncuria 10 plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platformsClinical Cancer Research · 2024
11. Abstract A002: Assessment of the diagnostic accuracy of Oncuria-Detect® for detection of upper tract urothelial carcinomaClinical Cancer Research · 2024
12. Abstract 3774: Evaluation of FibraChek™ for non-invasive detection of hepatic fibrosis and hepatocellular carcinomaCancer Research · 2024
13. Abstract 3773: Bladder cancer risk stratification with the Oncuria 10 plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platformsCancer Research · 2024
14. Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platformsJournal of Translational Medicine · 2024
15. Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms2023
16. A Diagnostic Gene Expression Signature for Bladder Cancer Can Stratify Cases into Prescribed Molecular Subtypes and Predict OutcomeDiagnostics · 2022
17. Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumorsJournal for ImmunoTherapy of Cancer · 2022
18. Clinical Utility of Oncuria™, a Multiplexed Liquid Biopsy for the Non-Invasive Detection of Bladder Cancer—A Pilot StudyDiagnostics · 2022
19. Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot studyCancer Biomarkers · 2021
20. Influencing Factors on the Oncuria™ Urinalysis Assay: An Experimental ModelDiagnostics · 2021